We recently reported (Pereira et al., Proc. Natl. Acad. Sci. U.S.A. 78:5202-5206, 1981) that herpes simplex virus 1 and 2 glycoproteins, previously designated gA and gB, could not be differentiated by a bank of independently derived typespecific and type-common monoclonal antibodies. We also reported that from lysates of infected Vero cells, all but one monoclonal antibody precipitated gA/B glycoproteins which had faster electrophoretic mobility than the corresponding infected HEp-2 cell glycoproteins and a set of three small polypeptides which we designated g(A+B) reactive polypeptides 1, 2, and 3. Antibody H368, the single exception, failed to react with the gA/B glycoproteins or related antigens accumulating in infected Vero cells. In this paper, we report the following results.
ports from this and other laboratories indicate that gA and gB glycoproteins are related, inasmuch as both reacted with monospecific antisera prepared against each glycoprotein (2) or with banks of independently derived monoclonal antibodies (10) . In the course of studies with the monoclonal antibodies, it was noted that gA/B glycoproteins made in Vero cells migrated significantly more rapidly than those made in HEp-2 cells. Furthermore, the infected Vero cell lysates contained three relatively small proteins which were precipitated by 23 of 24 monoclonal antibodies reactive with gA/B glycoprotein. The proteins were designated g(A+B) reactive polypeptides. The g(A+B) polypeptides of HSV-1 (F) had apparent molecular weights of 40,000, 39,000, and 29,000 and differed in electrophoretic mobility from those made by HSV-2 (G), which were 41,500, 37,000, and 27,000 in apparent molecular weight. The exception, monoclonal antibody H368, reacted with glycoprotein gA/B of HSV-2 made in HEp-2 cells but not with the gene product accumulating in Vero cells. These observations led to the suggestion that the differences in electrophoretic mobility of the glycoprotein gA/B made in Vero and HEp-2 cells could reflect differences in glycosylation or cleavage.
In this paper, we report that the electrophoretic mobility of glycoprotein gA/B very likely reflects the cleavage of the glycoprotein gene product in Vero cells, inasmuch as exposure of glycoprotein gA/B made in HEp-2 cells to uninfected Vero cell extracts resulted in proteolytic cleavage and yielded products indistinguishable from those accumulating in infected Vero cells. We also reinforce the conclusion that gA and gB glycoproteins and the g(A+B) reactive polypeptides are related by showing that they comap within the same restricted region of HSV DNA.
MATERIALS AND METHODS Viruses and cells. Isolation and properties of HSV-1 (mP), HSV-1 (F), and HSV-2 (G) strains and the derivation and properties of recombinants RH1G7, RH1G8, RH1G13, RH1G44, and RH1G48 were described previously (1, 3, 6, 7) . Human epidermoid carcinoma 2 (HEp-2) cells and African green monkey kidney (Vero) cells were grown in Earle minimum essential medium supplemented with 10%o fetal calf serum. After infection with virus, cells were maintained in medium containing 1% serum.
Monodonal antibodies to HSV. Hybridomas producing monoclonal antibodies to HSV glycoproteins were derived from fusion of BALB/c MOPC 21 NS-1 myeloma cells with spleen cells of BALB/c mice immunized with HSV. Procedures used for selection and characterization of hybridomas were published elsewhere (9a, 11) . Properties of H233 and H368 monoclonal antibodies to glycoproteins gA and gB were previously described (10) .
Preparation of radiolabeled infected cell extracts. HEp-2 or Vero cells, as indicated in the text, were infected with 10 PFU per cell and labeled with
[355]methionine (50 ,uCi/ml, >400 Ci/mmol; New England Nuclear Corp., Boston, Mass.) at 8 to 18 h postinfection. For pulse-chase experiments, infected cells were incubated in medium without methionine at 5 to 6 h postinfection. The cells were labeled for 15 min with [35S]methionine (100 ,Ci/ml) (pulse). Duplicate cultures replenished with medium containing unlabeled methionine were incubated for an additional 3 h (chase). Lysates of infected cells were prepared by incubating the cells on ice for 30 min in phosphatebuffered saline containing 1% Nonidet P-40 and 1% sodium deoxycholate. The antigen lysates were centrifuged for 60 min at 25,000 rpm and 4°C in a Beckman SW27.1 rotor.
Immunoprecipitation and polyacrylamide gel electrophoresis. Radiolabeled antigens were mixed with mouse ascites fluids (25 to 50 p,l) containing monoclonal antibodies. After incubation at room temperature for 60 min, rabbit anti-mouse immunoglobulin G (Miles Laboratories, Inc., Elkhart, Ind.), followed by protein A-Sepharose (Sigma Chemical Co., St. Louis, Mo.), were added to precipitate the antigen-antibody complexes. Immune precipitates adsorbed to protein ASepharose were washed repeatedly in cold phosphatebuffered saline containing 0.1% Nonidet P-40 and 1% sodium deoxycholate.
Denatured samples were subjected to electrophoresis in 9.25% polyacrylamide gels cross-linked with N,N-diallyltartardiamide and containing sodium dodecyl sulfate. Procedures for solubilization of the proteins, electrophoresis, and autoradiography were described previously (9) . Reagents used for polyacrylamide gel electrophoresis were purchased from Bio-Rad Laboratories, Richmond, Calif.
Incubation of infected HEp-2 cell lysates with uninfected Vero cell extracts. Uninfected Vero cell extracts were prepared from confluent cell sheets. The cells were harvested and incubated in phosphate-buffered saline containing 1% Nonidet P-40 and 1% sodium deoxycholate at 4°C for 30 min. Extracts were centrifuged as described above. Radiolabeled infected HEp-2 cell lysates were mixed with equal volumes (usually 25 ,ul) of uninfected Vero cell extracts and allowed to react for 60 min at room temperature. In some experiments, 10-' M N-a-p-tosyl-L-lysine chloromethyl ketone (TLCK), a trypsin inhibitor (14) , or L-1-tosylamide-2-phenylethyl chloromethyl ketone (TPCK), a chymotrypsin inhibitor (13) 
RESULTS
Electrophoretic mobility of proteins precipitated from infected HEp-2 and Vero cells by monoclonal antibody to glycoproteins gA/B after a pulse and after a chase. One unresolved question is whether the event underlying the difference in electrophoretic mobility of gA/B glycoprotein made in infected HEp-2 and Vero cells occurred during or immediately after translation or during delayed processing of the newly translated protein. To differentiate between these two possibilities, we compared the glycoprotein gA/B reactive antigens, labeled as described in Materials and Methods, in infected Vero and HEp-2 cells after a 15-min pulse and after a chase. Autoradiograms of the immune precipitated polypeptides electrophoretically separated in denaturing polyacrylamide gels are shown in Fig. 1 . The results showed the following.
(i) The event responsible for the difference in electrophoretic mobility of gA/B glycoproteins made in infected Vero and HEp-2 cells occurs during or soon after translation, inasmuch as the gA/B glycoproteins labeled during the pulse reflected the difference in electrophoretic mobility reported previously (10) .
(ii) The g(A+B) reactive polypeptides 2 and 3 .9m.
extracts ( Fig. 2 and 3 ). The cleavage was complete after 60 min. In addition to the more rapidly migrating forms of glycoproteins gA/B, the autoradiograms revealed the presence of g(A+B) reactive polypeptides 2 and 3 but not of 1.
To determine the nature of the proteolytic activity responsible for the cleavage, the mixtures were treated with TLCK and TPCK. The cleavage was inhibited by TLCK but not by TPCK ( Fig. 2 and 3) , suggesting that the proteolytic activity is trypsin-like with respect to amino acid specificity at the cleavage site. Furthermore, TLCK prevented cleavage not only in vitro but also in infected cells. Addition of TLCK 1 h before the addition of [35S]methionine to infected Vero cells precluded cleavage of glycoprotein gA/B (Fig. 4) .
In a previous report (10), we showed that, whereas 23 of 24 independently derived monoclonal antibodies reacted with gA/B glycopro- (Fig. 5) . The cleaved product, like the authentic product, did niot react with the H368 antibodies, suggesting that these antibodies are directed to an antigenic determinant site contained within the degraded or lost portion of the molecule.
Fine mapping of glycoproteins gA/B and g(A+B) reactive polypeptides. On the basis of electrophoretic mobilities of the glycoproteins specified by HSV-1 x HSV-2 recombinants, the glycoproteins gA and gB were mapped in a region of the HSV genome bounded by coordinates 0.30 to 0.42 map units (12) . More recent studies narrowed the coordinates of the gA/B genes to DNA BamHI fragment G (8) . This fragment maps between 0.337 and 0.388 map units. The experiments described below and concerned with more precise mapping of gA/B genes were done for two reasons. First, the narrowest map coordinates available do not exclude the possibility that the glycoproteins gA/B are specified by independent genes. The second reason concerned the g(A+B) reactive polypeptides. Previous studies have shown that g(A+B) reactive HSV-1 polypeptides differ in electrophoretic mobility from HSV-2 and that all monoclonal antibodies which precipitated glycoproteins gA/ B from infected Vero cell lysates also precipitated the g(A+B) reactive peptides (10) . Unambiguous demonstration that glycoprotein gA/B is a precursor of the g(A+B) reactive polypeptides requires evidence that the DNA sequences specifying the glycoprotein gA/B polypeptides and g(A+B) reactive peptides comap. The mapping of the DNA sequences specifying gA/B and g(A+B) took advantage of the availability of a set of suitable HSV-1 x HSV-2 recombinants produced by marker rescue of HSV-1 (mP) tsHAl with HSV-2 (G) DNA and monoclonal antibodies which react with either HSV-2 glycoproteins gA/B (e.g., H368) or with both HSV-1 and HSV-2 glycoproteins gA/B (e.g., H233). Figure 6 shows the maps of crossover sites in the DNAs of recombinants RH1G7, RH1G8, RH1G13, RH1G44, and RH1G48 described in detail by Conley et al. (1) . The map of the DNA of each recombinant is shown within the confines of a double line representing HSV-1 and HSV-2 DNAs (designated 1 and 2, respectively). The heavy line represents the DNA of the recombinant. The diagonal lines linking the lines representing HSV-1 and HSV-2 DNAs represent the approximate crossover sites. The crossover sites are based on the restriction endonuclease maps for HSV-1 (mP) and HSV-2 (G) DNAs shown in the lower portion of the figures.
The coordinates of the crossover sites differ slightly from those published by Conley et al. (1) , largely because the availability of cloned DNA fragments permitted a more precise alignment of the various restriction enzyme maps. As previously established, the HSV-2 sequences substituting HSV-1 sequences in RH1G7 have, as their maximum and minimum left boundaries, the restriction enzyme cleavage sites HSV-1 BamHI-T-J' and HSV-2 BglII-G-J, respectively; the maximum and minimum right boundaries are the HSV-2 KpnI-G-D and HSV-1 HpaI-B-H restriction enzyme cleavage sites, respectively. The left maximum and minimum boundaries of the HSV-2 sequences in RH1GH8 are defined by HSV-1 KpnI-N-P and HSV-2 BglII-J-O cleavage sites, respectively, whereas the right maximum and minimum boundaries are identical to those of RH1G7 DNA. The maximum and minimum left boundaries of HSV-2 sequences in RH1G13 are HSV-1 HpaI-I-V and -V-B cleavage sites, respectively; the maximum and minimum right boundaries are HSV-2 BglII-O-C and HSV-1 BamHI-R-W cleavage sites, respectively. In recombinant RH1G44, the maximum and minimum left HSV-2 boundaries are contained be- tween HSV-1 KpnI-J-M cleavage sites, whereas the right maximum and minimum boundaries are contained between the HSV-1 BamHI-R-W and HSV-1 KpnI-P-V cleavage sites. In the recombinant RH1G48, the left maximum and minimum boundaries of the HSV-2 sequences are identical to the corresponding boundaries of RH1G8 DNA; the right maximum and minimum boundaries are contained between HSV-1 BamHI-G-V and HSV-1 BamHI-V-R cleavage sites. Also shown is the map location of HSV-1 Sall fragment AO, which was shown to rescue the tsHAl mutation in marker rescue tests (1 those of the HSV-2 parent. Results of neutralization tests with monoclonal antibodies H233 and H368 and the RHlG series of recombinants are shown in Table 1 . The results are in accordance with immunoprecipitation reactions, in that type 2-specific monoclonal antibody H368 neutralized the HSV-2 (G) parent and recombinants RH1G7, RH1G13, RH1G44, and RH1G48 but failed to neutralize the HSV-1 parent and recombinant RH1G8.
Two features of the results shown in Fig. 6  through 8 are of significance. First, the g(A+B) reactive polypeptides generated in infected Vero cells by HSV-1 (mP) differ from those generated by HSV-1 (F), reinforcing the conclusion that the g(A+B) products are virus specific. The second aspect concerns the physical map location of the sequences specifying the HSV-2 antigenic determinants in the RHlG series of recombinants. The RHlG series of recombinants were selected by marker rescue of HSV-1 (mP) tsHAl with HSV-2 (G) DNA, and those shown in Fig. 7 and 8 specify HSV-2-infected cell polypeptide 8. Furthermore, the temperature-sensitive mutation was rescued by a small cloned fragment (SalI-AO) which selects from infected cells mRNA capable of translating in vitro the infected cell polypeptide 8. The temperature-sensitive mutation is, therefore, closely linked to the gene specifying polypeptide 8 . The results shown in Fig. 6 through 8 genome. (iii) The g(A+B) reactive polypeptides contain a significant fraction of the major antigenic determinants of glycoproteins gA/B, even though they represent somewhat less than 30o of the apparent molecular weight of the gA/B glycoproteins. This conclusion is based on the observation that all g(A+B) reactive polypeptides were precipitated by 23 of 24 independently derived monoclonal antibodies to glycoproteins gA/B. These monoclonal antibodies comprised 11 which neutralized the virus and 12 which did not. The exception was a monoclonal antibody (H368) which immunoprecipitated HSV-2 (G) glycoproteins gA/B made in HEp-2 but not those made in infected Vero cells. If the frequency of emergence of monoclonal antibodies per fractional length of the polypeptide reflected the density of antigenic determinant sites, it could be concluded that g(A+B) reactive polypeptide 1 from both HSV-1 and HSV-2 (apparent molecular weights, 29,000 and 27,000, respectively) contained a major portion of the type-common antigenic determinant sites of the parent gA/B glycoprotein molecule.
Location of the sequences specifying antigenic determinant sites of gA/B glycoproteins and g(A+B) reactive antigens on the physical map of the HSV genome. The availability of the RHlG series of HSV-1 x HSV-2 recombinants (1) permitted us to map the gene location of the sequences specifying the antigenic determinant sites of glycoproteins gA/B within a small portion of the region to which the gA and gB genes were previously assigned. Specifically, the earliest studies assigned the infected cell polypeptide 11 (9) and gA and gB genes (12) to 0.3 to 0.42 map units. In more recent studies, it was shown that the HSV-1-infected cell polypeptide 11 mapped at the right end of HSV-1 BamHI fragment G, immediately to the left of the gene specifying polypeptide 8. Because of the variability in electrophoretic patterns of glycoproteins gA/B reported earlier (12), it was not clear that the polypeptide 11 actually corresponds to glycoproteins gA/B, even though the genes specifying these polypeptides have consistently mapped in the same location. In this report, we show that the antigenic determinants of glycoproteins gA/B, as identified by immunoprecipitation with both type-common (H233) and HSV-2-specific (H368) monoclonal antibodies, map within BamHI-G to the right of the KpnI-N-P cleavage site but to the left of Sall fragment AO (Fig. 6) (i) We did not observe complete conversion of the gA/B glycoproteins made in infected HEp-2 cells into g(A+B) reactive polypeptides by cleavage with the enzyme contained in the uninfected Vero cell lysate. Similarly, both gA/B and g(A+B) reactive polypeptides accumulate in infected Vero cells even after a long chase. These observations suggest that only a portion of the gA/B precursor is cleaved to yield g(A+B) reactive polypeptides, and therefore, the cleavage sites which generate the g(A+B) reactive polypeptides must be inaccessible in some of the precursor molecules. Nothing is known regarding the fate of the peptides cleaved from gA/B precursor to generate the authentic infected Vero cell gA/B glycoproteins and the g(A+B) reactive polypeptides. Inasmuch as detection of such putative peptides requires antibody and since all but one monoclonal antibody were found to react with g(A+B) reactive polypeptides, we have no immunological reagents with which to determine whether the cleaved peptides are conserved or degraded in infected Vero cells.
(ii) The cleavage of gA/B precursor to yield the g(A+B) reactive polypeptides 2 and 3 and the gA/B molecules which accumulate in infected Vero cells must occur during or soon after the synthesis of the precursor, inasmuch as the products of the reaction were present in the lysates of cells harvested immediately after a 15-min pulse. In contrast, the g(A+B) reactive polypeptide 1 was not detected until after a chase. The proteolytic event which generates this polypeptide appears to occur later in the life of the gA/B polypeptide. The nature of the enzyme involved is not known.
(iii) The demonstration that the difference in electrophoretic mobilities is due to cleavage of the protein rather than to differences in the extent of glycosylation of glycoproteins gA/B in infected Vero and HEp-2 cells is of considerable significance. It indicates that differences in electrophoretic mobilities of HSV glycoproteins commonly observed when viruses are grown in different cell lines must be interpreted with caution, inasmuch as they may be due to partial proteolysis or to both cleavage and differential glycosylation.
(iv) Because the size of the virus yield from infected Vero cells is as high as or higher than that obtained from infected HEp-2 cells, the function of gA/B glycoproteins may not be affected by the proteolysis involved in generation of the authentic Vero infected cell gA/B glycoproteins. Whether g(A+B) reactive polypeptides are capable of expressing any of the functions of gA/B glycoproteins is currently unknown.
